



بسم الله الرحمن الرحيم

oooooo

تم رفع هذه الرسالة بواسطة / سنوي محمود عقل

بقسم التوثيق الإلكتروني بمركز الشبكات وتكنولوجيا المعلومات دون أدنى

مسئولية عن محتوى هذه الرسالة.

ملاحظات:

.....

.....

.....

.....

.....

.....



Detection of MicroRNA levels in amyotrophic lateral sclerosis patients

Thesis

Submitted for Partial Fulfillment of MD Degree
In Neurology

By

Radwa Mohammed Ahmed Soliman

(M.B.,B.Ch. M. Sc.)

Supervised by

Prof. Dr. Nagia Aly Fahmy

Professor of Neurology

Faculty of Medicine - Ain Shams University

Prof. Dr. Ahmed Osman Mostafa

Professor of Biochemistry

Faculty of science - Ain Shams University

Prof. Dr. Ramez Reda Moustafa

Professor of Neurology

Faculty of Medicine - Ain Shams University

Prof. Dr. Nabila Hamdi

Professor of Molecular Pathology

Faculty of science - German University *in Cairo*

Dr. Hebatallah R. Rashed

Associate Professor of Neurology

Faculty of Medicine - Ain shams University

Faculty of Medicine

Ain Shams University

2021

Acknowledgement

First and foremost, I would like to express my sincere gratitude to my advisor **Prof. Dr. Nagia Aly Fahmy, Professor of Neurology Faculty of Medicine, Ain Shams University**, for the continuous support she provides, for her patience, motivation, and immense knowledge. Her guidance helped me in all the time of research and work on this thesis. I could not have imagined having a better advisor and mentor for my M.D study.

My sincere thanks also goes to **Prof. Dr. Ahmed Osman, Professor of Biochemistry Ain Shams University** who has been extremely helpful and understanding throughout the work. Provided me an opportunity to join his team and gave access to the laboratory and research facilities. Without his precious support it would not have been possible to conduct this research.

I am also indebted to **Dr. Ramez M. Reda, Professor of Neurology, Faculty of Medicine, Ain Shams University** not only for his constant help, insightful comments and encouragement throughout this work, but also for the hard question which incited me to widen my research from various perspectives.

My deepest thanks and appreciation are extended to **Dr. Nabila Hamdi, Professor of Molecular Pathology, the German University in Cairo** who provided great help and important contributions to this work.

I also want to thank **Dr Hebatallah R. Rashed. Associate professor of Neurology, Ain Shams University**, Without her assistance and dedicated involvement in every step throughout the process, this thesis would have never been accomplished. I would like to thank you very much for your unlimited support and understanding over these past few years.

Of course I need to truly thank **Dr. Nahla O. Mousa , Lecturer of Science in Cairo University** for her immense help and guidance through each and every step in the practical laboratory work, her valuable contribution has made this work possible.

My sincere thanks to all staff members of neurology department, Faculty of Medicine, Ain Shams University for their support and kindness.

Many thanks and gratitude to my patients and their families for their cooperation and commitment.

Last but not the least, I would like to thank my family: my parents and to my brother and sister and my dear husband for always supporting me.

Radwa Soliman

List of Contents

Title	Page
▪ List of Abbreviations	I
▪ List of Tables	II
▪ List of Figures	IV
▪ Introduction	1
▪ Aim of the Work	4
▪ Review of Literature	
- Chapter (1): Amyotrophic Lateral Sclerosis	5
- Chapter (2): microRNA and its relations with ALS	36
▪ Methodology	66
▪ Results	71
▪ Discussion	108
▪ Summary	127
▪ Recommendations	131
▪ References	132
▪ Arabic Summary	--

List of Abbreviations

AHCs	Anterior Horn Cells
ALS	Amyotrophic Lateral Sclerosis
ALSFRS-R	ALS Functional Rating Scale
C9ORF	chromosome 9 Open Reading Frame
CNS	Central Nervous System
CSF	Cerebrospinal Fluid
ECAS	Edinburgh Cognitive and Behavioural ALS Screen
fALS	Familial ALS
FTD	Frontotemporal Degeneration
FUS	Fused in Sarcoma
Has	Homo Sapiens (Humans)
HC	Healthy Controls
miRNA	MicroRNA
MNs	Motor Neurons
MOCA	Montreal Cognitive Assessment
qPCR	Quantitative Polymerase Chain Reaction
sALS	Sporadic ALS
SOD1	Super Oxide Dismutase
TARDBP	TAR DNA-Binding Protein
TDB43	TAR DNA-Binding Protein 43

List of Tables

Table No.	Title	Page
Table (1):	Summary of most important ALS genes	10
Table (2):	Diagnostic tests for ALS	15
Table (3):	Prognostic factors of ALS.....	20
Table (4):	Differential diagnosis of ALS.....	26
Table (5):	Medications and dosages for symptomatic treatment	31
Table (6):	microRNAs and their changes in different tissues	48
Table (7):	Demographic data	72
Table (8):	History and clinical examination	74
Table (9):	Different risk factors and their frequency	76
Table (10):	Investigations.....	77
Table (11):	Patient MicroRNAs	78
Table (12):	Control MicroRNAs.....	78
Table (13):	Comparison between cases and controls regarding different MicroRNAs	79
Table (14):	Relation between MicroRNAs and presenting symptom.....	82

List of Tables (Continued)

Table No.	Title	Page
Table (15):	Relation between MicroRNAs and site of onset.....	83
Table (16):	Relation between MicroRNAs and clinical phenotype	84
Table (17):	Relation between MicroRNAs and extra-motor affection	84
Table (18):	Relation between MicroRNAs and cognitive function.....	85
Table (19):	Relation between smoking and MicroRNAs	86
Table (20):	Correlation between MicroRNAs and ALSFRS.....	86
Table (21):	Relation between MicroRNAs and Kings staging	87
Table (22):	Relation between MicroRNAs and mito staging	87
Table (23):	Relation between MicroRNAs and MOCA..	88
Table (24):	Relation between MicroRNAs and ECAS	88
Table (25):	Relation between MicroRNAs and NCS EMG.....	89
Table (26):	Comparison between familial cases and sporadic cases regarding clinical data (a).....	99
Table (27):	Comparison between familial cases and sporadic cases regarding clinical data (b)	100

List of Tables (Continued)

Table No.	Title	Page
Table (27):	Comparison between familial cases and sporadic cases regarding MiRNAs(c).....	101
Table (28):	Relation between patient's age at disease onset and clinical data (a)	103
Table (29):	Relation between patient's age at disease onset and clinical data (b)	104
Table (30):	Correlation between age, duration of illness and ALSFRS	105
Table (31):	Relation between smoking and ALSFRS.....	105
Table (32):	Correlation between age and MicroRNAs	106
Table (33):	Correlation between duration of illness and MicroRNAs.....	106
Table (34):	Correlation between disease progression rate and MicroRNAs.....	107
Table (35):	Rate of progression.....	107

List of Figures

Figure No.	Title	Page
Fig. (1):	Proposed pathogenic mechanisms and pathology in ALS	8
Fig. (2):	Different pathways induced by ALS proteins converge on translational repression	13
Fig. (3):	Staging systems for ALS	21
Fig. (4):	Principal events in miRNA biogenesis	42
Fig. (5):	miRNAs and their targets deregulated in ALS	56
Fig. (6):	Types of ALS	75
Fig. (7):	Presenting symptoms in ALS	75
Fig. (8):	Clinical phenotypes	76
Fig. (9):	MicroRNA206 between cases and control	80
Fig. (10):	MicroRNA143 between cases and control	80
Fig. (11):	Site of onset in Let7fp.....	83
Fig. (12):	MicroRNA4516 in affected and not affected cognitive function	85
Fig. (13):	Difference between sporadic and familial cases in MicroRNA4516	102

INTRODUCTION

Amyotrophic lateral sclerosis (ALS) is a fatal, adult-onset neurodegenerative disease. It is one of the motor neuron diseases in which motor neurons (MNs) are selectively lost. This progressive loss of MNs results in muscle denervation and atrophy, leading usually to death within 3-5 years of symptom onset (*Pasinelli and Brown, 2006; Rothstein, 2009*).

It is a common neurodegenerative disorder with an incidence of 1-2 / 100,000 and a prevalence of approximately 6/100,000 (*Shaw and Wood, 2010*).

There is no definitive diagnostic test for ALS; diagnosis is based on clinical findings, electromyography results and exclusion of mimics.

All suspected ALS patients should undergo electrophysiological testing which allows identification of Lower Motor Neuron features of ALS in both clinically affected and as yet clinically silent regions. In this way, the disease may be shown to be more widespread than is evident clinically and an earlier working diagnosis can be made. Typical electromyographic features of ALS include evidence of active denervation (positive sharp waves, fibrillation potentials, fasciculation potentials) and chronic denervation evidenced by large motor unit potentials (*Daube, 2000*).

-Introduction-

MicroRNAs (miRNAs) are small, regulatory RNAs that regulate the expression of protein-coding RNAs. miRNAs direct mRNA degradation or translational repression by partial binding to the 3'-UTR of mRNAs after first being incorporated into an RNA-induced silencing complex containing Argonaute-2 (Ago2) (*Gregory et al., 2005; Chekulaeva and Filipowicz, 2009; Ha and Kim, 2014*).

Emerging data demonstrate that miRNAs are powerful regulators of physiological and pathological cellular processes (*Naeini, 2010; O'Connell et al., 2010 and Sayed and Abdellatif, 2011*).

Therefore, miRNA expression is often dysregulated in disease and thus can be used as both diagnostic and therapeutic targets (*Chen et al., 2008; Koval et al., 2013*).

Because only partial complementarity is required for miRNA-mRNA interactions, a single miRNA can potentially regulate hundreds of mRNAs (*Selbach et al., 2008*).

MicroRNAs are 20 to 25 nucleotide-long noncoding transcripts that regulate biological processes via mRNA cleavage or translational repression of mRNA. There are over 1000 miRNAs in humans and they are typically measured using RNA sequencing. Overall, similar to the

-Introduction-

results in tissues from patients with ALS, most miRNAs levels are decreased in the CSF and serum of patients with ALS when compared with healthy and diseased controls. miRNA181a-5p, miRNA-143-5p, miRNA-574-5p, and miRNA-338-3p have been found to be increased in CSF from patients with ALS while miRNA 206, 106b and 181a-5p are thought to be increased in serum of patients with ALS (*Eitan and Hornstein, 2016; Benigni et al., 2016*).

A recent study showed reduced levels of miR-126-5p in pre-symptomatic ALS mice models, and a subsequent myocytes expression of diverse ALS-causing mutations promote axon degeneration and neuromuscular junction (NMJ) dysfunction, thus considering a novel mechanism underlying ALS pathology, in which alterations in miR126-5p facilitate a non-cell-autonomous mechanism of motor neuron degeneration in ALS and claimed that, overexpressing miR126-5p is sufficient to transiently rescue axon degeneration and NMJ disruption both in vitro and in vivo (*Maimon et al., 2018*).

AIM OF THE WORK

The aim of this study is to measure certain microRNAs in the plasma of amyotrophic lateral sclerosis patients versus normal controls, attempting to verify their potential role as possible biomarkers of the disease.

CHAPTER (1): AMYOTROPHIC LATERAL SCLEROSIS

Epidemiology of ALS:

The incidence of ALS is approximately 2.6 cases per 1000 00 persons annually, whereas the prevalence is approximately 6 cases per 100 000. Men have a higher incidence of disease than women (3/ 100000 compare to 2.4 /100000 person). In familial cases the incidence is the same. The average survival from onset to death is 3–4 years (*Logroscino et al., 2009*).

There is no population based study about ALS in Egypt, thus, there are no reports about the incidence or prevalence of ALS. This is due to the lack of specialized ALS centers across the country, which resulted in the absence of ALS registry and database. The delay in diagnosis results in delayed treatment with FDA approved medications and other symptomatic therapies (*Rashed & Tork, 2020*). In a recent Egyptian study, 30 patients were recruited from ALS clinic where they showed that the mean time from symptom onset to diagnosis (diagnostic delay) was 18.5 ± 16.3 months and the mean age at onset of symptoms was 52.6 ± 10.9 years (*Rashed & Tork, 2020*).

Environmental factors

Over the years a multitude of environmental exposure and lifestyle risk factors have been proposed as potential causes of ALS. The possible environmental factors evaluated include the intense physical activity, football, cigarette smoking, manual work, armed services and deployment, exposure to lead/solvents, pesticides and chemicals, heavy metal, electric shock, geographical clustering and cyanotoxins (*Al-Chalabi and Hardiman, 2013*).

Unfortunately, no conclusive data are available and further studies are needed to define exogenous risk factors for ALS (*Sutedja et al., 2009*). Interestingly, environmental exposures may result in heritable changes to genes, without altering the DNA sequence. This phenomenon is defined epigenetic and represents the most important point of convergence between genetic predisposition and environmental exposures (*Paez-Colasante et al., 2015*).

Pupillo and coworkers (2018) found evidence that certain foods and nutrients (red and processed meat, animal protein, and sodium, zinc and glutamic acid) were associated with a higher risk of ALS, whereas others (coffee, tea, whole bread, raw vegetables, and citrus fruits) might be associated with a lower risk of ALS but no